In the News

Learn about a hospital-wide program that empowers children before they undergo surgery at Memorial Sloan Kettering.

Learn how people with cancer can reduce insomnia during and after treatment.

There are more than 100 subtypes of brain tumors, making them a challenge to accurately diagnose. Now researchers have figured out a way to reliably distinguish them.

A family of drugs developed at MSK targets disrupted processes in cells in diseases related to aging.

Synovial sarcoma is an aggressive cancer primarily affecting children and young adults. A new study gets to the bottom of it.

Scientists are decoding the genetic changes that drive individual cancer cells. This may help them develop more-effective targeted therapies.

Because cancer is more treatable when it’s caught early, MSK’s new Precision Interception and Prevention initiative focuses on early detection.

An MSK medical oncologist and geneticist discusses the latest drug approved for breast cancer and how genetic testing can lead to new treatments.

Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine. The landmark data support the foundation of precision oncology by creating a treatment option for a genetically defined cancer while continuing to validate the concept that comprehensive molecular profiling should be strongly considered in people of all ages with advanced solid tumors.

MSK doctors and scientists are leading the charge to find new and innovative ways to treat metastatic brain cancer.